Transaction · 0001339375-26-000011

Riley Antony A

Riley Antony A, CFO, reported a transaction classified as unknown at Forte Biosciences, Inc. involving 42600.000000 shares. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

unknownSEC transaction code UCFO
FBRXForte Biosciences, Inc.
Trade date
Aug 27, 2026
Filing date
Aug 27, 2026
View on SEC Insider profile
Estimated value—Shares × reported price
Shares traded42.6kPrice unknown
Holdings after0Direct
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

FBRX price since this filing

Daily closing prices, with the filing date and available return windows
FBRX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -0.4%1w ago -0.1%1d ago +0.0%
Returns since7d +0.0%30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
unknown
Code U
Identifier
0001339375-26-000011
Common Stock
Transaction date
Aug 27, 2026
Filed Aug 27, 2026, 08:28 PM · 0d delay
Shares
42,600 sh
Price unknown
Estimated value
—
Computed from shares × price
Holdings after
0 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership
Filing-only score

+2 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 0

    Filing reported within two business days of the transaction.
  • missing_price-8 points

    price_cents is null

    Missing price reduces confidence in value-based signals.
Missing facts
  • price_cents
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CHIEF FINANCIAL OFFICER

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly…

  2. F2

    Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that…

  3. F3

    Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock.

  4. F4

    Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to an…

Original filing · 0001339375-26-000011
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

FBRX